$CYTK
CYTOKINETICS INC

2025 Q1 Form 10-K Financial Statement

#000095017025029206 Filed on February 27, 2025

View on sec.gov

Income Statement

Concept 2025 Q1 2024 Q4 2024
Revenue $18.47M
YoY Change 145.34%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $339.4M
YoY Change 2.81%
% of Gross Profit
Depreciation & Amortization $9.531M
YoY Change -19.85%
% of Gross Profit
Operating Expenses $554.7M
YoY Change 10.12%
Operating Profit -$536.2M
YoY Change 8.07%
Interest Expense $37.70M
YoY Change 33.19%
% of Operating Profit
Other Income/Expense, Net $51.53M
YoY Change 86.52%
Pretax Income
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$589.5M
YoY Change 12.03%
Net Earnings / Revenue -3190.97%
Basic Earnings Per Share -$5.26
Diluted Earnings Per Share -$5.26
COMMON SHARES
Basic Shares Outstanding 118.4M 118.0M 112.0K
Diluted Shares Outstanding 112.0K

Balance Sheet

Concept 2025 Q1 2024 Q4 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.076B
YoY Change 75.01%
Cash & Equivalents $94.86M
Short-Term Investments $981.2M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $16.65M
Other Receivables
Total Short-Term Assets $1.108B
YoY Change 76.41%
LONG-TERM ASSETS
Property, Plant & Equipment $65.82M
YoY Change -4.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.705M
YoY Change -3.64%
Total Long-Term Assets $293.7M
YoY Change 49.66%
TOTAL ASSETS
Total Short-Term Assets $1.108B
Total Long-Term Assets $293.7M
Total Assets $1.402B
YoY Change 70.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.37M
YoY Change -5.29%
Accrued Expenses $55.32M
YoY Change 29.74%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $11.52M
YoY Change 14.29%
Total Short-Term Liabilities $179.7M
YoY Change 74.99%
LONG-TERM LIABILITIES
Long-Term Debt $93.23M
YoY Change 59.68%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $93.23M
YoY Change 59.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $179.7M
Total Long-Term Liabilities $93.23M
Total Liabilities $1.537B
YoY Change 26.96%
SHAREHOLDERS EQUITY
Retained Earnings -$2.700B
YoY Change 28.57%
Common Stock $2.564B
YoY Change 48.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$135.4M
YoY Change
Total Liabilities & Shareholders Equity $1.402B
YoY Change 70.04%

Cashflow Statement

Concept 2025 Q1 2024 Q4 2024
OPERATING ACTIVITIES
Net Income -$589.5M
YoY Change 12.03%
Depreciation, Depletion And Amortization $9.531M
YoY Change -19.85%
Cash From Operating Activities -$395.9M
YoY Change -4.44%
INVESTING ACTIVITIES
Capital Expenditures $3.906M
YoY Change 175.85%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$553.1M
YoY Change -331.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $8.679M
YoY Change
Cash From Financing Activities 930.6M
YoY Change 320.49%
NET CHANGE
Cash From Operating Activities -395.9M
Cash From Investing Activities -553.1M
Cash From Financing Activities 930.6M
Net Change In Cash -18.17M
YoY Change -139.31%
FREE CASH FLOW
Cash From Operating Activities -$395.9M
Capital Expenditures $3.906M
Free Cash Flow -$399.8M
YoY Change -3.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001061983
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024 us-gaap Segment Reporting Codm Individual Title And Position Or Group Or Committee Name Extensible Enumeration
SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
http://fasb.org/srt/2024#ChiefExecutiveOfficerMember
CY2024Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilities
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-12-31
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
000-50633
CY2024 dei Entity Registrant Name
EntityRegistrantName
CYTOKINETICS, INCORPORATED
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3291317
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
350 Oyster Point Boulevard
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2024 dei City Area Code
CityAreaCode
650
CY2024 dei Local Phone Number
LocalPhoneNumber
624-3000
CY2024 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2024 dei Trading Symbol
TradingSymbol
CYTK
CY2024 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
false
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Public Float
EntityPublicFloat
5600000000
CY2025Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
118410689
CY2024 cyd Cybersecurity Risk Management Processes Integrated Flag
CybersecurityRiskManagementProcessesIntegratedFlag
true
CY2024 cyd Cybersecurity Risk Management Third Party Engaged Flag
CybersecurityRiskManagementThirdPartyEngagedFlag
true
CY2024 cyd Cybersecurity Risk Third Party Oversight And Identification Processes Flag
CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
true
CY2024 cyd Cybersecurity Risk Materially Affected Or Reasonably Likely To Materially Affect Registrant Flag
CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
true
CY2024 cyd Cybersecurity Risk Management Positions Or Committees Responsible Flag
CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
true
CY2024 cyd Cybersecurity Risk Management Positions Or Committees Responsible Report To Board Flag
CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
true
CY2024 dei Auditor Firm
AuditorFirmId
42
CY2024 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2024 dei Auditor Location
AuditorLocation
San Jose, California
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94857000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113024000
CY2024Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
981157000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
501800000
CY2024Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16650000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1283000
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15276000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11944000
CY2024Q4 us-gaap Assets Current
AssetsCurrent
1107940000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
628051000
CY2024Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
145055000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
40534000
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65815000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68748000
CY2024Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
75158000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
78987000
CY2024Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7705000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7996000
CY2024Q4 us-gaap Assets
Assets
1401673000
CY2023Q4 us-gaap Assets
Assets
824316000
CY2024Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
20369000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
21507000
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55323000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42641000
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18978000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17891000
CY2024Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11520000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
10080000
CY2024Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
11300000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2024Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
52370000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2024Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9814000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10559000
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
179674000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
102678000
CY2024Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
93227000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
58384000
CY2024Q4 cytk Convertible Notes Net
ConvertibleNotesNet
552370000
CY2023Q4 cytk Convertible Notes Net
ConvertibleNotesNet
548989000
CY2024Q4 cytk Liabilities Related To Revenue Participation Right Purchase Agreement Net
LiabilitiesRelatedToRevenueParticipationRightPurchaseAgreementNet
462192000
CY2023Q4 cytk Liabilities Related To Revenue Participation Right Purchase Agreement Net
LiabilitiesRelatedToRevenueParticipationRightPurchaseAgreementNet
379975000
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112582000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
120427000
CY2024Q4 cytk Liabilities Related To Rpi Transactions Fairvalue
LiabilitiesRelatedToRPITransactionsFairvalue
137000000
CY2023Q4 cytk Liabilities Related To Rpi Transactions Fairvalue
LiabilitiesRelatedToRPITransactionsFairvalue
0
CY2024Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
186000
CY2024Q4 us-gaap Liabilities
Liabilities
1537045000
CY2023Q4 us-gaap Liabilities
Liabilities
1210639000
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
118209139
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
118209139
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101637922
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101637922
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
118000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
102000
CY2024Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2563876000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1725823000
CY2024Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2398000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10000
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2701764000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2112238000
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-135372000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-386323000
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1401673000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
824316000
CY2024 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18474000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7530000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94588000
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
339408000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
330123000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
240813000
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
215314000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
173612000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
177977000
CY2024 us-gaap Operating Expenses
OperatingExpenses
554722000
CY2023 us-gaap Operating Expenses
OperatingExpenses
503735000
CY2022 us-gaap Operating Expenses
OperatingExpenses
418790000
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-536248000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-496205000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-324202000
CY2024 us-gaap Interest Expense
InterestExpense
37701000
CY2023 us-gaap Interest Expense
InterestExpense
28306000
CY2022 us-gaap Interest Expense
InterestExpense
19414000
CY2024 cytk Gain Loss On Extinguishment And Repurchase Of Debt Instrument
GainLossOnExtinguishmentAndRepurchaseOfDebtInstrument
0
CY2023 cytk Gain Loss On Extinguishment And Repurchase Of Debt Instrument
GainLossOnExtinguishmentAndRepurchaseOfDebtInstrument
0
CY2022 cytk Gain Loss On Extinguishment And Repurchase Of Debt Instrument
GainLossOnExtinguishmentAndRepurchaseOfDebtInstrument
-24939000
CY2024 cytk Non Cash Interest Expenses On Liabilities Related To Revenue Participation Right Purchase Agreements
NonCashInterestExpensesOnLiabilitiesRelatedToRevenueParticipationRightPurchaseAgreements
48811000
CY2023 cytk Non Cash Interest Expenses On Liabilities Related To Revenue Participation Right Purchase Agreements
NonCashInterestExpensesOnLiabilitiesRelatedToRevenueParticipationRightPurchaseAgreements
29362000
CY2022 cytk Non Cash Interest Expenses On Liabilities Related To Revenue Participation Right Purchase Agreements
NonCashInterestExpensesOnLiabilitiesRelatedToRevenueParticipationRightPurchaseAgreements
31742000
CY2024 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51534000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
27629000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11342000
CY2024 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1300000
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2024 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-19600000
CY2023 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0
CY2022 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-589526000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-526244000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-388955000
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.26
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.26
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.45
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.45
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.33
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.33
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111979
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111979
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96524
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96524
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89825
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89825
CY2024 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2153000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3600000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2721000
CY2024 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
255000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2024 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-587118000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-522664000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-391676000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
243863000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14316000
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
9602000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3227000
CY2022 cytk Stock Issued During Period Value Inducted Conversion Of Convertible Notes
StockIssuedDuringPeriodValueInductedConversionOfConvertibleNotes
-3378000
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2022 cytk Adjustments To Additional Paid In Capital Capped Call Options Associated With Convertible Notes
AdjustmentsToAdditionalPaidInCapitalCappedCallOptionsAssociatedWithConvertibleNotes
-26392000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
47853000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2721000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-388955000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-107900000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14319000
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2023 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
10517000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4140000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
72065000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3580000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-526244000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-386323000
CY2024 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48408000
CY2024 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2024 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
19631000
CY2024 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4608000
CY2024 cytk Stock Issue During Period Private Placement Value
StockIssueDuringPeriodPrivatePlacementValue
50000000
CY2024 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2024 cytk Stock Issued During Period Value Conversion Of Convertible Notes Value
StockIssuedDuringPeriodValueConversionOfConvertibleNotesValue
0
CY2024 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
97840000
CY2024 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2408000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-589526000
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-135372000
CY2024 us-gaap Profit Loss
ProfitLoss
-589526000
CY2023 us-gaap Profit Loss
ProfitLoss
-526244000
CY2022 us-gaap Profit Loss
ProfitLoss
-388955000
CY2024 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
48917000
CY2023 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
29474000
CY2022 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
31858000
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
97840000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
72065000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
47853000
CY2024 cytk Non Cash Lease Expense
NonCashLeaseExpense
4314000
CY2023 cytk Non Cash Lease Expense
NonCashLeaseExpense
3750000
CY2022 cytk Non Cash Lease Expense
NonCashLeaseExpense
2585000
CY2024 cytk Gain Loss On Dispose Of Property Plant Equipment
GainLossOnDisposeOfPropertyPlantEquipment
-45000
CY2023 cytk Gain Loss On Dispose Of Property Plant Equipment
GainLossOnDisposeOfPropertyPlantEquipment
0
CY2022 cytk Gain Loss On Dispose Of Property Plant Equipment
GainLossOnDisposeOfPropertyPlantEquipment
0
CY2024 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9531000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11892000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5814000
CY2024 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1300000
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2024 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-19600000
CY2023 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0
CY2022 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0
CY2024 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
19000
CY2023 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-35000
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-107000
CY2024 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-32515000
CY2023 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-15735000
CY2022 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-4710000
CY2024 us-gaap Paid In Kind Interest
PaidInKindInterest
11559000
CY2023 us-gaap Paid In Kind Interest
PaidInKindInterest
7341000
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
5697000
CY2024 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2693000
CY2024 us-gaap Gain Loss On Repurchase Of Debt Instrument
GainLossOnRepurchaseOfDebtInstrument
0
CY2023 us-gaap Gain Loss On Repurchase Of Debt Instrument
GainLossOnRepurchaseOfDebtInstrument
0
CY2022 us-gaap Gain Loss On Repurchase Of Debt Instrument
GainLossOnRepurchaseOfDebtInstrument
-22246000
CY2024 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15367000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1136000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-56672000
CY2024 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2438000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1596000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7414000
CY2024 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-4483000
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-3483000
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4524000
CY2024 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
52370000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-87000000
CY2024 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
14182000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
17103000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10844000
CY2024 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-7244000
CY2023 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1406000
CY2022 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1728000
CY2024 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1356000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-9585000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-4058000
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-395890000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-414333000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-299516000
CY2024 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1293416000
CY2023 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
635211000
CY2022 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
855393000
CY2024 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
744225000
CY2023 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
870905000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
604594000
CY2024 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2023 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
4975000
CY2022 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2024 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3906000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1416000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11335000
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-553097000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
239253000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-262134000
CY2024 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
939000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
858000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
944000
CY2024 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
8679000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
47651000
CY2024 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
CY2023 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
CY2022 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2409000
CY2024 cytk Repayment Of Convertible Debts
RepaymentOfConvertibleDebts
0
CY2023 cytk Repayment Of Convertible Debts
RepaymentOfConvertibleDebts
0
CY2022 cytk Repayment Of Convertible Debts
RepaymentOfConvertibleDebts
140330000
CY2024 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
523586000
CY2024 cytk Proceeds From Rpi Transactions Agreement
ProceedsFromRPITransactionsAgreement
200000000
CY2023 cytk Proceeds From Rpi Transactions Agreement
ProceedsFromRPITransactionsAgreement
50000000
CY2022 cytk Proceeds From Rpi Transactions Agreement
ProceedsFromRPITransactionsAgreement
149581000
CY2024 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
50000000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2024 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
53016000
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
18459000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
17543000
CY2024 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
19631000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
10517000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
9602000
CY2022 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
-26392000
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
930611000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
221317000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
516166000
CY2024 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
209000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-20000
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18167000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46217000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45484000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113399000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67182000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112666000
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95232000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113399000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67182000
CY2024 us-gaap Interest Paid Net
InterestPaidNet
25970000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
10295000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
15165000
CY2024 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
481000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10904000
CY2024 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1055000
CY2024 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3345000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
621000
CY2024 cytk Fair Value Of Stock Issued For Convertible Note
FairValueOfStockIssuedForConvertibleNote
0
CY2023 cytk Fair Value Of Stock Issued For Convertible Note
FairValueOfStockIssuedForConvertibleNote
0
CY2022 cytk Fair Value Of Stock Issued For Convertible Note
FairValueOfStockIssuedForConvertibleNote
317123000
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2700000000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-589500000
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-395900000
CY2024Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1221100000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
655400000
CY2024 cytk Cash Requirements Term
CashRequirementsTerm
P12M
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:27pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. We evaluate our estimates on an ongoing basis. We base our estimates on our historical experience and also on assumptions that we believe are reasonable; however, actual results could significantly differ from those estimates.</span></p>
CY2024 cytk Number Of Business Activity
NumberOfBusinessActivity
1
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024 us-gaap Segment Reporting Codm Profit Loss Measure How Used Description
SegmentReportingCodmProfitLossMeasureHowUsedDescription
Our chief operating decision maker (“CODM”) is our Chief Executive Officer ("CEO") who evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. The measures of profitability and the significant segment expenses reviewed by the CODM are consistent with these financial statements and footnotes. 
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:27pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash, cash equivalents, restricted cash, investments, and accounts receivable.</span></p><p style="text-indent:27pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cash, cash equivalents, restricted cash, and investments held with large financial institutions in the United States and deposits may exceed the Federal Deposit Insurance Corporation’s insurance limit.</span></p><p style="text-indent:27pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug candidates we develop may require approvals or clearances from the FDA or other regulatory agencies prior to commercial sales. There can be no assurance that our drug candidates will receive any of the required approvals or clearances. If we were to be denied approval, or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</span></p>
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94857000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113024000
CY2024Q4 us-gaap Restricted Cash
RestrictedCash
375000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
375000
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95232000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113399000
CY2024Q4 us-gaap Restricted Cash
RestrictedCash
400000
CY2024 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24875000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25759000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24853000
CY2022Q1 cytk Arrangement Consideration Of Debt Transaction
ArrangementConsiderationOfDebtTransaction
150000000
CY2024 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2023 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2024Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
102992000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
97096000
CY2024Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37177000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28348000
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65815000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68748000
CY2024 us-gaap Depreciation
Depreciation
9500000
CY2023 us-gaap Depreciation
Depreciation
11900000
CY2022 us-gaap Depreciation
Depreciation
5800000
CY2024Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
13567000
CY2023Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
5880000
CY2024Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
35132000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
29255000
CY2024Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6624000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7506000
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55323000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42641000
CY2024 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2700000
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2500000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1800000
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
19745000
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
40876000
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
558900000
CY2024Q4 us-gaap Long Term Debt
LongTermDebt
619521000
CY2024Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
58390000
CY2024Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
561131000
CY2024Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
8761000
CY2024Q4 cytk Convertible Notes Net
ConvertibleNotesNet
552370000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9372959
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.35
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
3424150
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
39.79
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.13
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
415675
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
28.94
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10992403
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.13
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2447225
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
38.59
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.13
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
458503
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
35.01
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11780230
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.07
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1551042
CY2024 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
60.13
CY2024 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
20.2
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
473893
CY2024 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
40.89
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10419523
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.84
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
178700000
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6879281
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.34
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2024Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
159500000
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
40.65
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.67
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.77
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
57500000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
51100000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
26900000
CY2024Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6000000
CY2024 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
97840000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
72065000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47853000
CY2024 cytk Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
12957
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
19563000
CY2024Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
204000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
20179000
CY2024Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
20514000
CY2024Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
20738000
CY2024Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
21403000
CY2024Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
88578000
CY2024Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
190975000
CY2024Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
204000
CY2024Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
59415000
CY2024Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
0
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
131560000
CY2024Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
204000
CY2024 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
19400000
CY2023 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
22100000
CY2022 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
21600000
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.01
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2024 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.05
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.04
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.04
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.24
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.24
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.26
CY2024 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.03
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.02
CY2024 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.04
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.03
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.02
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
282974000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
231915000
CY2024Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
146883000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
119815000
CY2024Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
102134000
CY2023Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
85501000
CY2024Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
43108000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
35466000
CY2024Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
133933000
CY2023Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
95437000
CY2024Q4 cytk Deferred Tax Assets Long Term Lease Liability
DeferredTaxAssetsLongTermLeaseLiability
25919000
CY2023Q4 cytk Deferred Tax Assets Long Term Lease Liability
DeferredTaxAssetsLongTermLeaseLiability
28634000
CY2024Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
734951000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
596768000
CY2024Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
5834000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
6842000
CY2024Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
15778000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
17392000
CY2024Q4 cytk Deferred Tax Liabilities Unrealized Loss
DeferredTaxLiabilitiesUnrealizedLoss
432000
CY2023Q4 cytk Deferred Tax Liabilities Unrealized Loss
DeferredTaxLiabilitiesUnrealizedLoss
6000
CY2024Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
22044000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
24240000
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
712907000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
572528000
CY2024Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2024 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
140400000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
128600000
CY2024 cytk Research And Development Federal Tax Credit Carryforwards Expiration Date Year
ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear
2025
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
25232000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18355000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11295000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
4438000
CY2024 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
97000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
97000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1804000
CY2024 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
5870000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6974000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
4426000
CY2024Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
31005000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
25232000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18355000
CY2024Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
30200000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
24500000
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
17700000
CY2021Q4 cytk Multinational Enterprises With Annual Global Revenue Excess Capital
MultinationalEnterprisesWithAnnualGlobalRevenueExcessCapital
750000000
CY2021Q4 cytk Payment Of A Global Minimum Tax Rate
PaymentOfAGlobalMinimumTaxRate
0.15
CY2021Q4 cytk Revenue Threshold
RevenueThreshold
750000000
CY2024Q4 ecd Insider Trd Policies Proc Adopted Flag
InsiderTrdPoliciesProcAdoptedFlag
true

Files In Submission

Name View Source Status
0000950170-25-029206-index-headers.html Edgar Link pending
0000950170-25-029206-index.html Edgar Link pending
0000950170-25-029206.txt Edgar Link pending
0000950170-25-029206-xbrl.zip Edgar Link pending
cytk-20241231.htm Edgar Link pending
cytk-20241231.xsd Edgar Link pending
cytk-ex10_21.htm Edgar Link pending
cytk-ex10_22.htm Edgar Link pending
cytk-ex10_33.htm Edgar Link pending
cytk-ex19_1.htm Edgar Link pending
cytk-ex23_1.htm Edgar Link pending
cytk-ex31_1.htm Edgar Link pending
cytk-ex31_2.htm Edgar Link pending
cytk-ex32_1.htm Edgar Link pending
cytk-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img258569631_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cytk-20241231_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending